MAAT PHARMA news, videos and press releases - Page 3
For more news please use our advanced search feature.
MAAT PHARMA - More news...
MAAT PHARMA - More news...
- MaaT Pharma Announces the Initiation of a Phase 2a Investigator-Sponsored Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors for Patients with Melanoma
- MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
- MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease
- MaaT Pharma Announces the Implementation of a Liquidity Contract with Kepler Cheuvreux
- MaaT Pharma to Present Promising Clinical Data for Lead Therapeutic Candidate MaaT013 at 48th EBMT Annual Meeting
- MaaT Pharma Reports Cash and Revenues for Full-Year 2021
- MaaT Pharma and Skyepharma Have Entered a Partnership to Establish the First Exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France
- MaaT Pharma Announces Ordinary and Extraordinary Shareholders’ General Meeting on March 3, 2022, and the Availability of Preparatory Documents
- MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study
- MaaT Pharma Provides Business Objectives and Expected Milestones for 2022
- MaaT Pharma Announces Initiation of Coverage of its Stock by KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas
- MaaT Pharma to Present at H.C. Wainwright BioConnect 2022 Virtual Conference
- MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting
- MaaT Pharma Announces the Partial Exercise of the Over-Allotment Option and the Total Size of the Offering at Approximately €35.7m
- MaaT Pharma Will Host Investor Information Meeting Following Presentation at ASH Conference of Additional Results on MaaT013
- MaaT Pharma to Provide Additional Results from Phase II Trial and Expanded Access Program on MaaT013 in Oral Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
- MaaT Pharma to Provide Additional Results from Phase II Trial and Expanded Access Program on MaaT013 in Oral Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
